PUREfi Wealth LLC Acquires 10,000 Shares of MeiraGTx Holdings PLC $MGTX

PUREfi Wealth LLC increased its holdings in shares of MeiraGTx Holdings PLC (NASDAQ:MGTX) by 100.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,000 shares of the company’s stock after purchasing an additional 10,000 shares during the quarter. PUREfi Wealth LLC’s holdings in MeiraGTx were worth $130,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of MGTX. GAMMA Investing LLC lifted its holdings in shares of MeiraGTx by 3,606.7% during the first quarter. GAMMA Investing LLC now owns 4,448 shares of the company’s stock valued at $30,000 after purchasing an additional 4,328 shares in the last quarter. CWM LLC lifted its holdings in MeiraGTx by 1,737.7% in the first quarter. CWM LLC now owns 8,674 shares of the company’s stock valued at $59,000 after acquiring an additional 8,202 shares during the period. Ieq Capital LLC bought a new position in MeiraGTx in the first quarter valued at about $83,000. Worth Venture Partners LLC bought a new position in MeiraGTx in the first quarter valued at about $217,000. Finally, Jump Financial LLC bought a new position in MeiraGTx in the first quarter valued at about $230,000. 67.48% of the stock is owned by institutional investors.

MeiraGTx Stock Performance

Shares of MGTX opened at $8.41 on Tuesday. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 26.29. The business has a 50-day simple moving average of $7.82 and a two-hundred day simple moving average of $6.94. The stock has a market cap of $676.56 million, a price-to-earnings ratio of -4.12 and a beta of 1.34. MeiraGTx Holdings PLC has a 52 week low of $3.97 and a 52 week high of $8.98.

MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. The business had revenue of $3.69 million during the quarter, compared to analysts’ expectations of $8.00 million. MeiraGTx had a negative return on equity of 314.44% and a negative net margin of 415.39%. On average, analysts expect that MeiraGTx Holdings PLC will post -1.48 EPS for the current year.

Insider Activity

In related news, CFO Richard Giroux sold 24,000 shares of the stock in a transaction dated Tuesday, July 22nd. The stock was sold at an average price of $8.52, for a total transaction of $204,480.00. Following the completion of the sale, the chief financial officer owned 853,494 shares in the company, valued at approximately $7,271,768.88. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.50% of the company’s stock.

Wall Street Analyst Weigh In

MGTX has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of MeiraGTx in a report on Saturday, September 27th. Wall Street Zen raised MeiraGTx from a “sell” rating to a “hold” rating in a report on Saturday, July 5th. Finally, Chardan Capital reissued a “buy” rating and issued a $35.00 target price on shares of MeiraGTx in a report on Friday, August 15th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $24.00.

MeiraGTx Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.